ArticleFrontiers in neurology2025
Association between finasteride with subjective memory deficits: a study from the NHANES and FAERS databases.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmarketing pharmacovigilance data have raised concerns regarding the potential cognitive effects associated with finasteride administration. However, existing epidemiological evidence remains inconclusive, with studies reporting both positive and null associations between finasteride exposure and memory dysfunction. This highlights the need for further comprehensive clinical investigations. Objective: This investigation employed a comprehensive, multi-source analytical approach to evaluate the potential correlation between finasteride administration and self-reported memory dysfunction, aiming to establish an evidence-based framework for clinical safety evaluation and therapeutic risk-benefit analysis. Methods: This study incorporated two principal data repositories: the National Health and Nutrition Examination Survey (NHANES, 2001-2018) and the Food and Drug Administration Adverse Event Reporting System (FAERS, 2004-2018). A comprehensive analytical framework was implemented, incorporating descriptive statistics, multivariable logistic regression modeling, and receiver operating characteristic (ROC) curve analysis to examine potential associations between finasteride exposure and cognitive performance metrics. Results: Multivariable logistic regression analysis of the NHANES dataset, adjusted for demographic variables and lifestyle factors, revealed a significant positive correlation between finasteride exposure and memory impairment risk (adjusted OR = 6.15, 95% CI: 1.62-23.4, Conclusion: Convergent evidence from both epidemiological studies and pharmacovigilance surveillance suggests a potential association between finasteride administration and cognitive dysfunction, particularly in memory-related domains. These findings underscore the need for comprehensive risk communication strategies regarding potential neurocognitive adverse effects during clinical consultations and for establishing routine cognitive monitoring protocols for patients undergoing prolonged finasteride therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.